Serum Endocannabinoid Levels in Patients with End-Stage Renal Disease
Moradi, Hamid et al. (2019), Serum Endocannabinoid Levels in Patients with End-Stage Renal Disease, v2, UC Irvine Dash, Dataset, https://doi.org/10.7280/D18W95
Context: Previous studies have shown that the endocannabinoid system, through the actions of its main mediators 2-arachidonoyl-sn-glycerol (2-AG) and anandamide (AEA), plays a major role in the energy metabolism.
Objective: We examined serum levels of major endocannabinoid mediators and their association with clinical parameters in patients with end-stage renal disease (ESRD) .
Design and Setting: Serum concentrations of 2-AG and AEA were measured in patients on maintenance hemodialysis (MHD) and correlations with various clinical and laboratory indices were examined. For comparison of levels in MHD patients, 2-AG was also measured in healthy subjects, advanced CKD (stage IV), and peritoneal dialysis (PD) patients.
Main Outcome Measure: Serum 2-AG.
Results: Serum 2-AG levels were significantly elevated in patients with CKD and ESRD when compared to healthy controls. Highest levels of 2-AG were found in MHD patients, and these findings were similarly seen in a second set of subjects in independent analyses. Among 96 MHD patients, 2-AG levels correlated significantly and positively with serum triglycerides (Rho=0.43, P<0.0001), body mass index (Rho=0.40, P<0.0001) and body anthropometric measures, and negatively with serum high-density lipoprotein cholesterol (Rho= -0.33, P=0.001) following adjustment for demographic and clinical variables.
Conclusions: In MHD patients, serum 2-AG – a major endocannabinoid mediator – levels were found to be increased. In addition, increasing serum 2-AG levels correlated with increased serum triglycerides and markers of body mass. Future studies will need to evaluate the potential mechanisms responsible for these findings.